State slower to ‘adopt new drugs’ than most of western Europe

31 May 2021 - Medicines regularly not worth approving at asking price. ...

Read more →

External reference pricing: the drug pricing reform America needs?

27 May 2021 - External reference pricing, sometimes known as international reference pricing, refers to the practice of informing price negotiations ...

Read more →

Americans paid two to four times as much for some drugs as in three other countries

28 April 2021 - Amid national angst over the cost of prescription drugs, a new analysis finds that U.S. consumers ...

Read more →

International reference pricing for prescription drugs in the United States: administrative limitations and collateral effects

12 April 2021 - Many countries use international (or external) reference pricing—benchmarking prices against those in other countries—to manage spending ...

Read more →

Regulatory policy may not stop comparative efficacy trials

4 November 2020 - The way Sarfaraz K. Niazi, looks at it, doing comparative efficacy studies in humans to confirm that ...

Read more →

Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study

7 October 2020 - The investigators of the study set out to characterise the therapeutic value of new drugs approved ...

Read more →

Sophisticated purchasing of pharmaceuticals: learning from other countries

28 September 2020 - In 2019 and early 2020, drug pricing in the United States was a top concern of ...

Read more →

FDA publishes comparative performance data for COVID-19 molecular diagnostic tests

15 September 2020 - Today, the U.S. FDA published comparative performance data for some authorised COVID-19 molecular diagnostic tests.  ...

Read more →

Biocon, Mylan launch Semglee and seek biosimilar, interchangeable status

31 August 2020 - For all intents and purposes, Semglee is a biosimilar insulin, but official biosimilar status is needed to ...

Read more →

International reference pricing: discounts down under far surpass U.S. drug price concessions

1 September 2020 - At 30,000 feet, the view of Australia’s healthcare system does not look too different from our own ...

Read more →

Direct or indirect comparison: reliance on innovative drug data key to engaging data protection

15 August 2020 - The Federal Court recently issued its decision in Natco v Canada (Minister of Health), 2020 FC 788, ...

Read more →

PBAC asks Roche for another comparison for Tecentriq

20 July 2020 - The submission requested a PBS (Section 100) listing for atezolizumab for use in combination with taxane chemotherapy ...

Read more →

Assessing quantitative comparisons of health and social care between countries

15 July 2020 - Cross-national comparisons in health care and social care may offer insight into quality and cost.  ...

Read more →

International reference pricing gets thumbs down from ISPOR panel

18 May 2020 - International reference pricing, by which drug prices would be pegged to international standards, is under consideration ...

Read more →

A comparison of the EQ-5D-3L and EQ-5D-5L

12 May 2020 - Previous studies have found the EQ-5D-5L to have superior measurement properties but no study has compared ...

Read more →